$GMTX News
Last published 8mo ago
- 8mo agoWVEDNLIMRNAGMTX+6FDA reversals leave investors worrying about the fates of other experimental drugsCNBCInvestors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
- 3y agoGMTXDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaPR NewswireWATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 3y agoGMTXDisc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual MeetingPR NewswireWATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious
- 4y agoGMTXDisc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual MeetingPR NewswireCAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from
- 4y agoGMTXDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)PR NewswireAURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United StatesAURORA study designed to assess changes in protoporphyrin IX levels, safety, tolerability,
- 4y agoGMTXGemini Therapeutics and Disc Medicine Announce Merger AgreementBusiness WireMerger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine's portfolio of hematology programs Combined company is expected to have approximately $175 million of cash or cash equivalents at close, in
- 4y agoGMTXGemini Therapeutics Reports 2021 Financial ResultsBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX) today reported financial results for the year ended December 31, 2021. "As previously announced this year, Gemini Therapeutics has initiated a process to evaluate strategic options to maximize shareholder value
- 4y agoGMTXGemini Therapeutics Provides Corporate UpdateBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, s
- 4y agoGMTXGemini Therapeutics Provides GEM103 Program UpdateBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of G
- 4y agoBBBLUGMTXOCGN+1Thinking about buying stock in BELLUS Health, Gemini Therapeutics, BlackBerry, Reliance Global Group, or Ocugen?PR NewswireNEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GMTX, BB, RELI, and OCGN. To
- 4y agoGMTXGemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness WireGEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta Phase 2a study Expect to provide six-month update from GEM103 ReGAtta study by year-end Scheduled to meet with the FDA i
- 5y agoGMTXGemini Therapeutics Announces Poster Presentation at AAO 2021Business WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Profe
- 5y agoGMTXGemini Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini
- 5y agoGMTXGemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development SummitBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced Chief Medical Officer, Samuel Barone, M.D., will presen
- 5y agoGMTXGemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of inducement awards under Gemini's 2021 Indu
- 5y agoGMTXGemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic AtrophyBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced a corporate restructuring, including several exec
- 5y agoALXOCYTGMTXLightstone Ventures Raises $375 Million FundPR NewswireMENLO PARK, Calif. and BOSTON, Sept. 14, 2021 /PRNewswire/ -- Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and
- 5y agoGMTXGemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement TherapeuticsBusiness Wire- Studies show mechanism of action and biodistribution of GEM103 and support continued development as a potential treatment for AMD Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments
- 5y agoGMTXGemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 VirtualBusiness Wire- Study shows well-tolerated safety profile with no increased risk of CNV, complement regulation, reduction in inflammatory state and supports bi-monthly dosing Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company dev
- 5y agoGMTXGemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini
- 5y agoGMTXGemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the SummitBusiness Wire- GEM103 biological activity in intraocular compartment showed ability of potential first in class complement regulator to inhibit C3 activation and amplification - GEM103 continues to be well tolerated and intraocular pharmacokinetics support advanc
- 5y agoGMTXGemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV - Completed enrollment in Phase 2a study of GEM10
- 5y agoGMTXGemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology ConferenceBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini
- 5y agoGMTXGemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationBusiness Wire– Biomarker results indicate GEM103's ability to regulate complement and complement factor H therapeutic approach in geographic atrophy – – GEM103 continues to be well-tolerated and demonstrates a differentiated safety profile with no increased
- 5y agoGMTXGemini Therapeutics to Participate in the Jefferies Virtual Healthcare ConferenceBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini
- 5y agoGMTXGemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire- Fast Track Designation for GEM103 in dry AMD granted January 2021 - GEM103 Phase 2a study in geographic atrophy data on track for June 2021 - GEM103 Phase 2a as a possible add-on therapy for patients with wet AMD at risk for macular atrophy com
- 5y agoGMTXGemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular AtrophyBusiness Wire-Topline data expected in late 2021 Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion o
- 5y agoGMTXGemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of DirectorsBusiness WireGemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges
- 5y agoGMTXGemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingBusiness Wire− GEM103 demonstrates anti-angiogenic activity in a mouse model of laser-induced choroidal neovascularization (CNV) Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for geneticall
- 5y agoGMTXGemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini’s Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini’s Chief Medical Offi ...
- 5y agoGMTXGemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical OfficerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately.
- 5y agoGMTXGemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdateBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today reported its financial results for the year ended December 31, 2020 and provided a business update.
- 5y agoGMTXGemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual ...
- 5y agoGMTXGemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic VariantsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the completion of enrollment in its Phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement ...
- 5y agoGMTXGemini Therapeutics Appoints Brian Piekos as Chief Financial OfficerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini.